TY - JOUR AU - Barkai, L. J. AU - Gonczi, L. AU - Farkas, K. AU - Farkas, B. AU - Molnar, T. AU - Szamosi, T. AU - Schafer, E. AU - Golovics, P. AU - Juhasz, M. AU - Patai, A. AU - Vincze, Áron AU - Sarlós, Patrícia AU - Farkas, A. AU - Dubravcsik, Z. AU - Toth, T. G. AU - Miheller, P. AU - Lakatos, P. L. AU - Ilias, A. TI - Ustekinumab in Crohn's disease: A three-year multicentre prospective study from Hungary - Assessing efficacy, drug sustainability, and safety JF - JOURNAL OF CROHNS & COLITIS J2 - J CROHNS COLITIS VL - 18 PY - 2024 SP - I1249 EP - I1249 PG - 1 SN - 1873-9946 UR - https://m2.mtmt.hu/api/publication/34803210 ID - 34803210 N1 - Supplement: 1 LA - English DB - MTMT ER - TY - JOUR AU - Szemes, Kata AU - Borbásné Farkas, Kornélia AU - Sipos, Zoltán AU - Bor, Renáta AU - Fábián, Anna AU - Szepes, Zoltán AU - Farkas, Klaudia AU - Molnár, Tamás AU - Schafer, Eszter AU - Szamosi, Tamas AU - Salamon, Agnes AU - Vincze, Áron AU - Sarlós, Patrícia TI - Co-Administration of Proton Pump Inhibitors May Negatively Affect the Outcome in Inflammatory Bowel Disease Treated with Vedolizumab JF - BIOMEDICINES J2 - BIOMEDICINES VL - 12 PY - 2024 IS - 1 PG - 13 SN - 2227-9059 DO - 10.3390/biomedicines12010158 UR - https://m2.mtmt.hu/api/publication/34509107 ID - 34509107 N1 - Division of Gastroenterology, First Department of Medicine, Medical School, University of Pécs, 13 Ifjúság Street, Pecs, 7624, Hungary Institute of Bioanalysis, Medical School, University of Pécs, Pecs, 7624, Hungary First Department of Medicine, University of Szeged, Szeged, 6720, Hungary Department of Gastroenterology, Hungarian Defence Forces Military Hospital, Budapest, 1134, Hungary Balassa János Hospital, Szekszárd, 7100, Hungary Institute for Translational Medicine, Medical School, University of Pécs, Pecs, 7624, Hungary Export Date: 6 February 2024 Correspondence Address: Sarlos, P.; Division of Gastroenterology, 13 Ifjúság Street, Hungary; email: sarlos.patricia@pte.hu AB - Concomitant medications may alter the effect of biological therapy in inflammatory bowel disease. The aim was to investigate the effect of proton pump inhibitors on remission rates in patients with inflammatory bowel disease treated with the gut-selective vedolizumab. Patients from the Hungarian nationwide, multicenter vedolizumab cohort were selected for post hoc analysis. Primary outcomes were the assessment of clinical response and endoscopic and clinical remission at weeks 14 and 54. Secondary outcomes were the evaluation of the combined effect of concomitant steroid therapy and other factors, such as smoking, on remission. A total of 108 patients were identified with proton pump inhibitor data from 240 patients in the original cohort. Patients on steroids without proton pump inhibitors were more likely to have a clinical response at week 14 than patients on concomitant PPI (95% vs. 67%, p = 0.005). Non-smokers with IBD treated with VDZ were more likely to develop a clinical response at week 14 than smokers, particularly those not receiving PPI compared with patients on co-administered PPI therapy (81% vs. 53%, p = 0.041, and 92% vs. 74%, p = 0.029, respectively). We found that the use of PPIs in patients treated with VDZ may impair the achievement of response in certain subgroups. Unnecessary PPI prescriptions should be avoided. LA - English DB - MTMT ER - TY - JOUR AU - Nagy, Rita AU - Ocskay, Klementina AU - Sipos, Zoltán AU - Szentesi, Andrea Ildikó AU - Vincze, Áron AU - Czakó, László AU - Izbéki, Ferenc AU - Shirinskaya, Natalia V AU - Poluektov, Vladimir L AU - Zolotov, Alexandr N AU - Zhu, Yin AU - Xia, Liang AU - He, Wenhua AU - Sutton, Robert AU - Szatmary, Peter AU - Mukherjee, Rajarshi AU - Burridge, Isobel Saffron AU - Wauchope, Emma AU - Francisco, Elsa AU - Aparicio, David AU - Pinto, Bruno AU - Gomes, António AU - Nunes, Vitor AU - Tantau, Vasile Marcel AU - Sagau, Emanuela Denisa AU - Tantau, Alina Ioana AU - Suceveanu, Andra Iulia AU - Tocia, Cristina AU - Dumitru, Andrei AU - Pando, Elizabeth AU - Alberti, Piero AU - Cirera, Arturo AU - Molero, Xavier AU - Lee, Hong Sik AU - Jung, Min Kyu AU - Kim, Eui Joo AU - Lee, Sanghyub AU - Rebollo, María Lourdes Ruiz AU - Nistal, Reyes Busta AU - Santervas, Sandra Izquierdo AU - Lesko, Dusan AU - Soltes, Marek AU - Radonak, Jozef AU - Zatorski, Hubert AU - Małecka-Panas, Ewa AU - Fabisiak, Adam AU - Yaroslav, M Susak AU - Mykhailo, V Maksymenko AU - Olekcandr, A Tkachenko AU - Barauskas, Giedrius AU - Simanaitis, Vytautas AU - Ignatavicius, Povilas AU - Jinga, Mariana AU - Balaban, Vasile-Daniel AU - Patoni, Cristina AU - Gong, Liang AU - Song, Kai AU - Li, Yunlong AU - Gonçalves, T Cúrdia AU - Freitas, Marta AU - Macedo, Vítor AU - Vornhuelz, Marlies AU - Klauss, Sarah AU - Beyer, Georg AU - Koksal, Aydin Seref AU - Tozlu, Mukaddes AU - Eminler, Ahmet Tarik AU - Monclús, Nuria Torres AU - Comas, Eva Pijoan AU - Oballe, Juan Armando Rodriguez AU - Nawacki, Łukasz AU - Głuszek, Stanisław AU - Rama-Fernández, Alberto AU - Galego, Marco AU - de la Iglesia, Daniel AU - Aykut, Umut Emre AU - Duman, Deniz Güney AU - Aslan, Rahmi AU - Gherbon, Adriana AU - Deng, Lihui AU - Huang, Wei AU - Xia, Qing AU - Poropat, Goran AU - Radovan, Anja AU - Vranić, Luka AU - Ricci, Claudio AU - Ingaldi, Carlo AU - Casadei, Riccardo AU - Negoi, Ionut AU - Ciubotaru, Cezar AU - Iordache, Florin Mihail AU - Constantinescu, Gabriel AU - Sandru, Vasile AU - Altintas, Engin AU - Balci, Hatice Rizaoglu AU - Constantino, Júlio AU - Aveiro, Débora AU - Pereira, Jorge AU - Gunay, Suleyman AU - Misirlioglu Sucan, Seda AU - Dronov, Oleksiy AU - Kovalska, Inna AU - Bush, Nikhil AU - Rana, Surinder Singh AU - Chooklin, Serge AU - Chuklin, Serhii AU - Saizu, Ionut Adrian AU - Gheorghe, Cristian AU - Göltl, Philipp AU - Hirth, Michael AU - Mateescu, Radu Bogdan AU - Papuc, Geanina AU - Minkov, Georgi Angelov AU - Enchev, Emil Tihomirov AU - Mastrangelo, Laura AU - Jovine, Elio AU - Chen, Weiwei AU - Zhu, Quping AU - Gąsiorowska, Anita AU - Fabisiak, Natalia AU - Bezmarevic, Mihailo AU - Litvin, Andrey AU - Mottes, Martina Cattani AU - Choi, Eun Kwang AU - Bánovčin, Peter AU - Nosáková, Lenka AU - Kovacheva-Slavova, Mila Dimitrova AU - Kchaou, Ali AU - Tlili, Ahmed AU - Marino, Marco V AU - Kusnierz, Katarzyna AU - Mickevicius, Artautas AU - Hollenbach, Marcus AU - Molcan, Pavol AU - Ioannidis, Orestis AU - Tokarev, Mark Valerievich AU - Ince, Ali Tüzün AU - Semenenko, Ivan Albertovich AU - Galeev, Shamil AU - Ramírez-Maldonado, Elena AU - Sallinen, Ville AU - Pencik, Petr AU - Bajor, Judit AU - Sarlós, Patrícia AU - Hágendorn, Roland AU - Gódi, Szilárd AU - Szabó, Imre AU - Czimmer, József AU - Pár, Gabriella AU - Illés, Anita AU - Faluhelyi, Nándor AU - Kanizsai, Péter László AU - Nagy, Tamás AU - Mikó, Alexandra AU - Németh, Balázs AU - Hamvas, József AU - Bod, Barnabás AU - Varga, Márta AU - Török, Imola AU - Novák, János AU - Patai, Árpád AU - Sümegi, János AU - Góg, Csaba AU - Papp, Mária AU - Erőss, Bálint Mihály AU - Váncsa, Szilárd AU - Teutsch, Brigitta AU - Márta, Katalin AU - Hegyi, Péter Jenő AU - Tornai, Tamás AU - Lázár, Balázs AU - Hussein, Tamás AU - Tarján, Dorottya AU - Lipp, Mónika Bernadett AU - Kovács, Beáta AU - Urbán, Orsolya AU - Fürst, Emese Rita AU - Tari, Edina AU - Kocsis, Ibolya AU - Maurovich-Horvat, Pál AU - Tihanyi, Balázs AU - Eperjesi, Orsolya AU - Kormos, Zita AU - Deák, Pál Ákos AU - Párniczky, Andrea AU - Hegyi, Péter TI - Discharge protocol in acute pancreatitis: an international survey and cohort analysis JF - SCIENTIFIC REPORTS J2 - SCI REP VL - 13 PY - 2023 IS - 1 PG - 10 SN - 2045-2322 DO - 10.1038/s41598-023-48480-z UR - https://m2.mtmt.hu/api/publication/34434496 ID - 34434496 AB - There are several overlapping clinical practice guidelines in acute pancreatitis (AP), however, none of them contains suggestions on patient discharge. The Hungarian Pancreatic Study Group (HPSG) has recently developed a laboratory data and symptom-based discharge protocol which needs to be validated. (1) A survey was conducted involving all members of the International Association of Pancreatology (IAP) to understand the characteristics of international discharge protocols. (2) We investigated the safety and effectiveness of the HPSG-discharge protocol. According to our international survey, 87.5% (49/56) of the centres had no discharge protocol. Patients discharged based on protocols have a significantly shorter median length of hospitalization (LOH) (7 (5;10) days vs. 8 (5;12) days) p < 0.001), and a lower rate of readmission due to recurrent AP episodes (p = 0.005). There was no difference in median discharge CRP level among the international cohorts (p = 0.586). HPSG-protocol resulted in the shortest LOH (6 (5;9) days) and highest median CRP (35.40 (13.78; 68.40) mg/l). Safety was confirmed by the low rate of readmittance (n = 35; 5%). Discharge protocol is necessary in AP. The discharge protocol used in this study is the first clinically proven protocol. Developing and testifying further protocols are needed to better standardize patients' care. LA - English DB - MTMT ER - TY - JOUR AU - Martonosi, Ágnes Rita AU - Németh, Balázs Csaba AU - Párniczky, Andrea AU - Vincze, Áron AU - Szentesi, Andrea Ildikó AU - Erőss, Bálint Mihály AU - Sahin-Tóth, Miklós AU - Hegyi, Péter AU - Hegyi, Eszter TI - CFTR p.F508del Mutation Carrier Status Is Not Associated With Biliary Acute Pancreatitis JF - PANCREAS J2 - PANCREAS VL - 52 PY - 2023 IS - 4 SP - e256 EP - e257 SN - 0885-3177 DO - 10.1097/MPA.0000000000002241 UR - https://m2.mtmt.hu/api/publication/34196830 ID - 34196830 LA - English DB - MTMT ER - TY - JOUR AU - Juhász, Márk Félix AU - Tóháti, Rebeka AU - Jászai, Viktória Adrienn AU - Molnár, Regina AU - Borbásné Farkas, Kornélia AU - Czakó, László AU - Vincze, Áron AU - Erőss, Bálint Mihály AU - Szentesi, Andrea Ildikó AU - Izbéki, Ferenc AU - Papp, Mária AU - Hegyi, Péter AU - Párniczky, Andrea ED - Váncsa, Szilárd / Collaborator ED - Márta, Katalin / Collaborator ED - Földi, Mária / Collaborator ED - Nagy, Rita / Collaborator ED - Hegyi, Péter Jenő / Collaborator ED - Ocskay, Klementina / Collaborator ED - Imrei, Marcell / Collaborator ED - Mikó, Alexandra / Collaborator ED - Gódi, Szilárd / Collaborator ED - Bajor, Judit / Collaborator ED - Hágendorn, Roland / Collaborator ED - Sarlós, Patrícia / Collaborator ED - Szabó, Imre / Collaborator ED - Czimmer, József / Collaborator ED - Faluhelyi, Nándor / Collaborator ED - Kanizsai, Péter / Collaborator ED - Nagy, Tamás / Collaborator ED - Gajdán, László / Collaborator ED - Kui, Balázs / Collaborator ED - Illés, Dóra / Collaborator ED - Takács, Tamás / Collaborator ED - Vitális, Zsuzsanna / Collaborator ED - Hamvas, József / Collaborator ED - Varga, Márta / Collaborator ED - Bod, Barnabás / Collaborator ED - Novák, János / Collaborator ED - Maurovich-Horvat, Pál / Collaborator ED - Doros, Attila / Collaborator ED - Deák, Pál Ákos / Collaborator ED - Varga, Csaba / Collaborator ED - Gaál, Szabolcs / Collaborator ED - Zubek, László / Collaborator ED - Gál, János / Collaborator ED - Lázár, Balázs / Collaborator ED - Hussein, Tamás / Collaborator ED - Kovács, Bea / Collaborator ED - Tarján, Dorottya / Collaborator ED - Lipp, Mónika Bernadett / Collaborator ED - Urbán, Orsolya / Collaborator ED - Tornai, Tamás / Collaborator TI - Invalidity of Tokyo guidelines in acute biliary pancreatitis : A multicenter cohort analysis of 944 pancreatitis cases JF - UNITED EUROPEAN GASTROENTEROLOGY JOURNAL J2 - UEG JOURNAL VL - 11 PY - 2023 IS - 8 SP - 767 EP - 774 PG - 8 SN - 2050-6406 DO - 10.1002/ueg2.12402 UR - https://m2.mtmt.hu/api/publication/34072590 ID - 34072590 N1 - * Megosztott szerzőség AB - There is a noteworthy overlap between the clinical picture of biliary acute pancreatitis (AP) and the 2018 Tokyo guidelines currently used for the diagnosis of cholangitis (AC) and cholecystitis (CC). This can lead to significant antibiotic and endoscopic retrograde cholangiopancreatography (ERCP) overuse.We aimed to assess the on-admission prevalence of AC/CC according to the 2018 Tokyo guidelines (TG18) in a cohort of biliary AP patients, and its association with antibiotic use, ERCP and clinically relevant endpoints.We conducted a secondary analysis of the Hungarian Pancreatic Study Group's prospective multicenter registry of 2195 AP cases. We grouped and compared biliary cases (n = 944) based on the on-admission fulfillment of definite AC/CC according to TG18. Aside from antibiotic use, we evaluated mortality, AC/CC/AP severity, ERCP performance and length of hospitalization. We also conducted a literature review discussing each criteria of the TG18 in the context of AP.27.8% of biliary AP cases fulfilled TG18 for both AC and CC, 22.5% for CC only and 20.8% for AC only. Antibiotic use was high (77.4%). About 2/3 of the AC/CC cases were mild, around 10% severe. Mortality was below 1% in mild and moderate AC/CC patients, but considerably higher in severe cases (12.8% and 21.2% in AC and CC). ERCP was performed in 89.3% of AC cases, common bile duct stones were found in 41.1%.Around 70% of biliary AP patients fulfilled the TG18 for AC/CC, associated with a high rate of antibiotic use. Mortality in presumed mild or moderate AC/CC is low. Each of the laboratory and clinical criteria are commonly fulfilled in biliary AP, single imaging findings are also unspecific-AP specific diagnostic criteria are needed, as the prevalence of AC/CC are likely greatly overestimated. Randomized trials testing antibiotic use are also warranted. LA - English DB - MTMT ER - TY - JOUR AU - Turcsiné Czapári, Dóra AU - Váradi, Alex AU - Borbásné Farkas, Kornélia AU - Nyári, Gergely Róbert AU - Márta, Katalin AU - Váncsa, Szilárd AU - Nagy, Rita AU - Teutsch, Brigitta AU - Bunduc, Stefania AU - Erőss, Bálint Mihály AU - Czakó, László AU - Vincze, Áron AU - Izbéki, Ferenc AU - Papp, Mária AU - Merkely, Béla Péter AU - Szentesi, Andrea Ildikó AU - Hegyi, Péter ED - Péter, Jenő Hegyi / Collaborator ED - Andrea, Párniczky / Collaborator ED - Mária, Földi / Collaborator ED - Klementina, Ocskay / Collaborator ED - Márk, Félix Juhász / Collaborator ED - Imrei, Marcell / Collaborator ED - Szabolcs, Kiss / Collaborator ED - Alexandra, Mikó / Collaborator ED - Szilárd, Gódi / Collaborator ED - Judit, Bajor / Collaborator ED - Roland, Hágendorn / Collaborator ED - Patrícia, Sarlós / Collaborator ED - Imre, Szabó / Collaborator ED - József, Czimmer / Collaborator ED - Nándor, Faluhelyi / Collaborator ED - Péter, Kanizsai / Collaborator ED - Attila, Miseta / Collaborator ED - Tamás, Nagy / Collaborator ED - László, Gajdán / Collaborator ED - Adrienn, Halász / Collaborator ED - Németh, Balázs / Collaborator ED - Kui, Balázs / Collaborator ED - Illés, Dóra / Collaborator ED - Takács, Tamás / Collaborator ED - Tiszlavicz, László / Collaborator ED - Oláh, Orsolya / Collaborator ED - Radics, Bence / Collaborator ED - Vitális, Zsuzsanna / Collaborator ED - József, Hamvas / Collaborator ED - Márta, Varga / Collaborator ED - Barnabás, Bod / Collaborator ED - János, Novák / Collaborator ED - Pál, Maurovich-Horváth / Collaborator ED - Doros, Attila / Collaborator ED - Pál, Ákos Deák / Collaborator ED - Varga, Csaba / Collaborator ED - Szabolcs, Gaál / Collaborator ED - László, Zubek / Collaborator ED - János, Gál / Collaborator ED - Zsolt, Molnár / Collaborator ED - Tamás, Tornai / Collaborator ED - Balázs, Lázár / Collaborator ED - Tamás, Hussein / Collaborator ED - Beáta, Kovács / Collaborator ED - Anna, Németh / Collaborator ED - Tarján, Dorottya / Collaborator ED - Lipp, Mónika Bernadett / Collaborator ED - Orsolya, Urbán / Collaborator ED - Simon, Tóth / Collaborator ED - Dániel, Söti / Collaborator ED - Dávid, Becker / Collaborator TI - Detailed characteristics of post-discharge mortality in acute pancreatitis JF - GASTROENTEROLOGY J2 - GASTROENTEROLOGY VL - 165 PY - 2023 IS - 3 SP - 682 EP - 695 PG - 14 SN - 0016-5085 DO - 10.1053/j.gastro.2023.05.028 UR - https://m2.mtmt.hu/api/publication/33864451 ID - 33864451 N1 - * Megosztott szerzőség AB - The in-hospital survival of patients suffering from acute pancreatitis (AP) is 95-98%. However, there is growing evidence that patients discharged after AP may be at risk of serious morbidity and mortality. Here, we aimed to investigate the risk, causes, and predictors of the most severe consequence of the post-AP period: mortality.2,613, well-characterized patients from twenty-five centers were collected and followed by the Hungarian Pancreatic Study Group between 2012 and 2021. A general and a hospital-based population was used as the control group.After an AP episode patients have an approximately three-fold higher incidence rate of mortality than the general population (0.0404vs.0.0130 person-years). First-year mortality after discharge was almost double than in-hospital mortality (5.5%vs.3.5%), with 3.0% occurring in the first 90-day period. Age, comorbidities, and severity were the most significant independent risk factors for death following AP. Furthermore, multivariate analysis identified creatinine, glucose, and pleural fluid on admission as independent risk factors associated with post-discharge mortality. In the first 90-day period, cardiac failure and AP-related sepsis were among the main causes of death following discharge, while cancer-related cachexia and non-AP-related infection were the key causes in the later phase.Almost as many patients in our cohort die in the first 90-day period after discharge as during their hospital stay. Evaluation of cardiovascular status, follow-up of local complications, and cachexia-preventing oncological care should be an essential part of post-AP patient care. Future study protocols in AP must include at least a 90-day follow-up period after discharge. LA - English DB - MTMT ER - TY - JOUR AU - Herszényi, László AU - Aradi, Dániel AU - Békássy, Szabolcs AU - Járai, Zoltán AU - Juhász, Márk AU - Kiss, Róbert Gábor AU - Kolossváry, Endre AU - Nardai, Sándor AU - Simonyi, Gábor AU - Szőnyi, Mihály AU - Tomcsányi, János AU - Torzsa, Péter AU - Tulassay, Zsolt AU - Vincze, Áron AU - Becker, Dávid TI - Gasztroenterológiai-kardiológiai multidiszciplináris konszenzus a hatékony gasztroprotekció szükségességéről antitrombotikus kezelés alkalmazásakor : A Magyar Gasztroenterológiai Társaság és a Magyar Kardiológusok Társaságának közös állásfoglalása JF - CARDIOLOGIA HUNGARICA J2 - CARDIOL HUNG VL - 53 PY - 2023 IS - 2 SP - 150 EP - 159 PG - 10 SN - 0133-5596 DO - 10.26430/CHUNGARICA.2023.53.2.150 UR - https://m2.mtmt.hu/api/publication/33862757 ID - 33862757 AB - Az antitrombotikus (thrombocytaaggregáció-gátló – TAG és antikoaguláns) szerek alkalmazása nélkülözhetetlen a szív- és érrendszeri (kardiovaszkuláris – CV) betegségek kezelésében. Az antitrombotikus szerek alkalmazása azonban növeli a tápcsatornai vérzések kockázatát. A megelőzés során a CV és a gasztrointesztinális (GI) kockázati tényezőket egyaránt figyelembe kell venni és hatékony gyomornyálkahártya-védelmet (gasztroprotekciót) kell alkalmazni. A gasztroprotekció alapja a hatékony savszekréció-gátlás. A protonpumpagátló (PPI)-szerek biztosítják a leghatékonyabb gasztroprotekciót. Az antitrombotikus kezelés során az esetek egy részében nem történik hatékony gasztroprotekció, amely a PPI elégtelen alkalmazásával magyarázható. A hatékony gasztroprotekciót illetően jelenleg nem áll rendelkezésre naprakész magyar útmutató vagy ajánlás. A közlemény a legújabb evidenciák tükrében, elismert hazai kardiológus és gasztroenterológus szakértők multidiszciplináris konszenzusa alapján összefoglalja az antitrombotikus kezelés során alkalmazandó gasztroprotekció legfontosabb gyakorlati szempontjait. LA - Hungarian DB - MTMT ER - TY - JOUR AU - Czakó, László AU - Gyökeres, Tibor Zoltán AU - Hritz, István AU - Madácsy, László AU - Illés, Dóra AU - Szepes, Zoltán AU - Dubravcsik, Zsolt AU - Péterfi, Zoltán AU - Nagy, András AU - Szűcs, Ákos AU - Vincze, Áron TI - Epeút- és epehólyag-gyulladás: diagnosztikus kritériumok és terápia [Cholangitis and cholecystitis: diagnostic criteria and management] JF - ORVOSI HETILAP J2 - ORV HETIL VL - 164 PY - 2023 IS - 20 SP - 770 EP - 787 PG - 18 SN - 0030-6002 DO - 10.1556/650.2023.32770 UR - https://m2.mtmt.hu/api/publication/33842885 ID - 33842885 N1 - Belgyógyászati Klinika, Gasztroenterológiai Osztály, Általános Orvostudományi Kar, Szegedi Tudományegyetem, Szeged, Hungary Gasztroenterológiai Osztály, ÉSzak-Pesti Centrumkórház - Honvédkórház, Budapest, Hungary Sebészeti, Transzplantációs és Gasztroenterológiai Klinika, Általános Orvostudományi Kar, Semmelweis Egyetem, Budapest, Hungary Endo-Kapszula Magánorvosi Centrum, Székesfehérvár, Hungary Gasztroenterológiai Osztály, Bács-Kiskun Megyei Oktatókórház, Kecskemét, Hungary I. Belgyógyászati Klinika, Általános Orvostudományi Kar, Pécsi Tudományegyetem, Pécs, Hungary Radiológiai Klinika, Általános Orvostudományi Kar, Szegedi Tudományegyetem, Szeged, Hungary Export Date: 7 September 2023 CODEN: ORHEA Correspondence Address: László, C.Pf. 469, Hungary; email: czako.laszlo@med.u-szeged.hu AB - In developed countries, diseases of the gallbladder and the biliary tract count as some of the most frequent gastrointestinal disorders. The inflammation of the gallbladder/biliary tree is a potentially severe, even lethal condition that requires rapid diagnosis and early multidisciplinary approach to be treated. Although the frequency of these diseases is high, the treatment is not unified in Hungary yet. The aim of the evidence-based recommendation is to clarify the diagnostic criteria and severity grading of these diseases and to highlight the indications and rules of proper application of the numerous available therapeutic interventions. The recent guideline is based on the consensus of the Board members of the Endoscopic Section of the Hungarian Gastroenterology Society in contribution with renown experts of surgery, infectology as well as interventional radiology and it counts as a clear and easy applicable guide during the all-day healthcare practice. Our guidelines are based on Tokyo guidelines established on the basis of the consensus reached in the International Consensus Meeting held in Tokyo which were revised in 2013 (TG13) and in 2018 (TG18). Orv Hetil. 2023; 164(20): 770-787. LA - Hungarian DB - MTMT ER - TY - JOUR AU - Sarlós, Patrícia AU - Bikar, Alexander AU - Borbásné Farkas, Kornélia AU - Resál, Tamás AU - Szepes, Zoltán AU - Farkas, Klaudia AU - Nagy, Ferenc AU - Vincze, Áron AU - Miheller, Pál AU - Molnár, Tamás TI - Self-reported efficacy and safety of infliximab and adalimumab biosimilars after non-medical switch in patients with inflammatory bowel disease: results of a multicenter survey JF - EXPERT OPINION ON BIOLOGICAL THERAPY J2 - EXPERT OPIN BIOL TH VL - 23 PY - 2023 IS - 8 SP - 827 EP - 832 PG - 6 SN - 1471-2598 DO - 10.1080/14712598.2023.2211204 UR - https://m2.mtmt.hu/api/publication/33826696 ID - 33826696 N1 - Department of Medicine, University of Pecs Medical School, Pecs, Hungary Institute for Translational Medicine, University of Pecs Medical School, Pecs, Hungary Department of Medicine, University of Szeged Albert Szent-Györgyi, Szeged, Hungary Department of Surgery, Transplantation and Gastroenterology, Semmelweis University, Budapest, Hungary Export Date: 22 November 2023 CODEN: EOBTA Correspondence Address: Sarlós, P.; Department of Medicine, 13 Ifjúság Street, Hungary; email: sarlosp@gmail.com Chemicals/CAS: adalimumab, 331731-18-1, 1446410-95-2; infliximab, 170277-31-3; Adalimumab; Biosimilar Pharmaceuticals; Gastrointestinal Agents; Infliximab; Tumor Necrosis Factor Inhibitors Tradenames: gp 1111; gp 2017; humira; hyrimoz; remicade; zessly AB - Few data are available on subjective disease control and perception of adverse events (AEs) during switching from original anti-TNF agents to biosimilars.Hungarian patients with inflammatory bowel disease were interviewed after a mandatory non-medical switch from an infliximab (IFX) originator to a biosimilar GP1111 or from an adalimumab (ADA) originator to a biosimilar GP2017. Drug choice was based on patient's and physician's decision. Subjective efficacy was measured using a 10-point scale, and AEs were assessed. Difference in efficacy before and after the switch was compared within and between the drugs.Seventy-three ADA and 106 IFX switching patients were interviewed. Subjective efficacy of IFX biosimilar was rated lower compared to IFX originator (8.72 ± 1.68 vs. 7.77 ± 2.34; p = 0.001). The ADA biosimilar was rated higher than its originator (9.02 ± 1.61 vs. 8.42 ± 1.93; p = 0.017). Patients receiving ADA biosimilar were more satisfied with the new treatment compared to IFX (p = 0.032). The incidence of new AEs was 85% in the ADA and 55% in the IFX group (1.79 vs. 0.93 AEs per patient, respectively, p < 0.001).Subjective efficacy of switching to a biosimilar was proven in case of ADA, while reduced efficacy was experienced with IFX biosimilar. Perception of AEs was high and varied between biosimilars. LA - English DB - MTMT ER - TY - JOUR AU - Vincze, Áron TI - Endoscopic diagnosis and treatment in gastric cancer : Current evidence and new perspectives JF - FRONTIERS IN SURGERY J2 - FRONT SURG VL - 10 PY - 2023 PG - 5 SN - 2296-875X DO - 10.3389/fsurg.2023.1122454 UR - https://m2.mtmt.hu/api/publication/33770177 ID - 33770177 AB - Gastric cancer is the fifth most common cause of cancer related deaths worldwide. Despite advancement in endoscopic techniques, the majority of the cases are diagnosed at late stage, when the curative treatment options are very limited. The early gastric cancer (EGC) on the other side is potentially curable, and in selected cases endoscopic resection techniques offer similar survival rates then surgical resection. The detection of EGC is endoscopically challenging and requires high quality examination. Recent data show that close to 10% of the gastric cancer cases had a previous negative endoscopy. This highlights the urgent need to improve the quality of the endoscopy services, what can be achieved by increasing the awareness of gastroenterologists and continuously monitoring the key performance indicators of upper gastrointestinal endoscopy. Newer endoscopic imaging techniques are also becoming commonly available to aid the detection of gastric premalignant lesions and EGC. High-definition endoscopy with image enhancement techniques is preferred over white light endoscopy to recognize these lesions, and they are also useful to determine the invasion depth of EGC. The endoscopic optical characterization of lesions is necessary for the selection of proper resection method and decide whether endoscopic resection techniques can be considered. Artificial intelligence systems aid the detection of EGC and can help to determine the depth of invasion. Endoscopic mucosal resection and endoscopic submucosal dissection requires centralized care and tertiary referral centers with appropriate expertise to ensure proper patient selection, high success rate and low adverse event rate. Appropriately scheduled endoscopic surveillance of high-risk patients, premalignant lesions and after resection of EGC is also important in the early detection and successful treatment of gastric cancer. LA - English DB - MTMT ER -